Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis

One Sentence Summary: PET imaging of CCR2⁺ cells in lung fibrosis identifies a therapeutic response in mouse models and displays a perifibrotic signal in subjects with IPF.

Steven L. Brody^{1,2,*}, Sean P. Gunsten¹, Hannah P. Luehmann², Debbie H. Sultan², Michelle Hoelscher², Gyu Seong Heo², Jiehong Pan¹, Jeffrey R. Koenitzer¹, Ethan C. Lee¹, Tao Huang¹, Cedric Mpoy³, Shuchi Guo¹, Richard Laforest², Amber Salter⁴, Tonya D. Russell¹, Adrian Shifren¹, Christophe Combadiere⁵, Kory J. Lavine^{1,5}, Daniel Kreisel^{6,7}, Benjamin D. Humphreys¹, Buck E. Rogers³, David S. Gierada², Derek E. Byers¹, Robert J. Gropler^{1,2}, Delphine L. Chen^{2,†}, Jeffrey J. Atkinson¹, and Yongjian Liu^{2,*}

¹Department of Medicine, Washington University School of Medicine, Saint Louis, MO USA.

²Department of Radiology, Washington University School of Medicine, Saint Louis, MO USA.

³Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO USA.

⁴Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO USA.

⁵Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO USA.

⁶Department of Surgery, Washington University School of Medicine, Saint Louis, MO USA.

⁷Department of Immunology and Pathology, Washington University School of Medicine, Saint Louis, MO USA.

⁵Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, F-75013, Paris, FR.

[†]Current address: Seattle Cancer Care Alliance, Department of Radiology, University of Washington, Seattle, WA, USA.

*Co-corresponding authors:

Steven L Brody, Washington University School of Medicine, Box 8052, 660 South Euclid Avenue, Saint Louis, MO 63110, USA; Tel.: (314) 362-8969; E-mail: brodys@wustl.edu

Yongjian Liu, Washington University School of Medicine, Box 8225 510 South Kingshighway Boulevard, Saint Louis, MO 63110, USA; Tel.: (314) 362-8431; E-mail: yongjianliu@wustl.edu

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, inflammatory lung disease that is monitored clinically by measures of lung function, without effective molecular markers of disease activity or therapeutic efficacy. Lung immune cells active in the pro-fibrotic process include inflammatory monocyte and interstitial macrophages that express the C-C motif chemokine receptor 2 (CCR2). CCR2⁺ monocyte lung influx is essential for disease phenotypes in models of fibrosis and identified in lungs from subjects with IPF. Here, we show that our peptide-based radiotracer ⁶⁴Cu-DOTA-ECL1i identifies CCR2⁺ inflammatory monocytes and interstitial macrophages in multiple preclinical mouse models of lung fibrosis, using positron emission tomography (PET) imaging. Mice with bleomycin-induced fibrosis treated with blocking antibodies to interleukin-1 β , a mediator of fibrosis associated with CCR2⁺ cell inflammation, or with pirfenidone, an approved anti-fibrotic agent, demonstrated decreased CCR2-dependent interstitial macrophage accumulation and reduced ⁶⁴Cu-DOTA-ECL1i PET uptake, compared to controls. Lung tissues from patients with fibrotic lung disease demonstrated abundant CCR2⁺ cells surrounding regions of fibrosis, and an ex vivo tissue-binding assay showed correlation between radiotracer localization and CCR2⁺ cells. In a phase 0/1 clinical study of ⁶⁴Cu-DOTA-ECL1i PET, healthy volunteers showed little lung uptake, while subjects with pulmonary fibrosis exhibited increased uptake, notably in zones of subpleural fibrosis, reflecting the distribution of CCR2⁺ cells in the profibrotic niche. These findings support a pathologic role of inflammatory lung monocytes/macrophages in fibrotic lung disease and the translational use of ⁶⁴Cu-DOTA-ECL1i PET to track CCR2-specific inflammation for image-guided therapy.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterized by interstitial macrophage accumulation, fibroblast proliferation, and matrix deposition of uncertain pathogenesis (1). Patients have a clinical course that ranges from slow progression to rapid deterioration and an overall five-year survival of 20 to 40% (2). Anti-fibrotic therapies are limited; pirfenidone and nintedanib are currently the only approved medications for IPF (3, 4). These drugs slow disease progression but have a limited positive impact on survival (3, 4). However, there is currently no way to predict the individual patient's response to a specific therapy, nor are there established markers to monitor the molecular or cellular response to a treatment. Particular to IPF, bronchoalveolar lavage, and especially lung biopsy, are often avoided due to clinical status and a tendency to worsen disease (5, 6). Thus, the development of a non-invasive, molecular assessment may address these challenges to improve patient care and the therapeutic pipeline.

A major gap in IPF care remains a paucity of tools to define patient-specific molecular phenotypes, including lung or serum markers to follow the course of disease. Substantial efforts to develop non-invasive testing, such as genetic signatures in peripheral leukocytes, have been imprecise, though elevated levels of circulating CD14⁺ monocytes are recently suggested to predict mortality (7). Clinically, features of fibrosis present on high resolution chest computed tomography (CT) are used for diagnosis and can predict mortality (5, 6). The primary biomarkers used to follow disease are pulmonary function test parameters: forced vital capacity (FVC), diffusion capacity for carbon monoxide, and the distance walked in 6 minutes (5, 8). While these tests validate changes in pulmonary physiology, they are indirect measures of disease outcome (3, 6, 8). Most physiologic measures do not reverse with effective therapeutics and instead primarily reflect irreversible remodeling rather than a measure of profibrotic activity.

CCR2⁺ (C-C motif chemokine receptor 2) cells have a context-dependent activity in the fibrotic lung and represent a rational marker of inflammation in fibrotic disease. In vivo studies show that elevated levels of lung tissue CCL2 (C-C motif chemokine ligand 2) contribute to lung fibrosis by directing Ly6C^{high}, CCR2⁺ inflammatory (classical) monocyte egress from the bone marrow to the lung (9, 10). *Ccr2*-deficient mice have markedly attenuated development of lung fibrosis induced by bleomycin, radiation, and other pro-fibrotic irritants (11-13). In lung fibrosis models, lineage

tracing and single cell transcriptome analysis show that CCR2⁺ monocytes accumulate in the lung and differentiate into cells referred to as inflammatory monocyte-derived macrophages, interstitial macrophages, or tissue macrophages (10, 14, 15). In humans, CCR2-dependent bone marrow-derived monocytes and interstitial macrophages are increased in samples taken from the lungs of patients with pulmonary fibrosis (15-17). CCR2⁺ monocytes and macrophages produce factors that induce fibroblast recruitment and collagen production including TGFβ, implicating the interstitial macrophages in the pro-fibrotic process (14-21). However, the temporal infiltration and differentiation of CCR2⁺ monocytes relative to degree of inflammation or fibrosis is not well known in experimental models nor is their distribution in human fibrotic lungs well described. Moreover, scant detail exists regarding the therapeutic effects of existing anti-fibrotic drugs on CCR2⁺ and CCR2-derived populations (22, 23). A detailed map of CCR2⁺ cells in the fibrotic lung would be essential for evaluating the role of CCR2 in emerging molecular-based therapies.

Recently, our group reported on the development of a peptide-based radiotracer, ⁶⁴Cu-DOTA-ECL1i, to quantify the CCR2-specific inflammatory cell burden using positron emission tomography (PET) in pre-clinical models. The sensitivity and specificity of ⁶⁴Cu-DOTA-ECL1i for imaging CCR2⁺ cell trafficking was demonstrated in experimental lung injury induced by endotoxin or reperfusion, atherosclerosis, and myocardial injury in mice (24-27). Application of this radiotracer for clinical use in patients with pulmonary fibrosis is attractive based on the requirement for CCR2⁺ immune cells in experimental models and their presence in human diseased lungs. Also compelling are the clinical challenges of managing patients with IPF in the face of a paucity of actionable molecular markers of disease activity. Accordingly, we used mouse models to study the late stages of lung fibrosis induced by bleomycin and ionizing radiation to establish that increased ⁶⁴Cu-DOTA-ECL1i PET uptake in the lung correlates with CCR2⁺ cell infiltration associated with fibrosis. We then demonstrated that therapeutic modulation of fibrosis by using anti-IL-1β to block activity in interstitial macrophages or treatment with the anti-fibrotic drug pirfenidone, decreased the PET uptake signal to provide a unique clinically applicable measure. We advanced the radiotracer to first-in-human use in patients with pulmonary fibrosis to reveal increased uptake in regions of subpleural fibrosis in the lung. The findings suggest the clinical relevance of CCR2 as a molecular target for pulmonary fibrosis and support the translational use of ⁶⁴Cu-DOTA-ECL1i to monitor CCR2-specific inflammatory cell activity. Future applications

may facilitate the development of targeted therapies that alter CCR2-mediated profibrotic remodeling.

Results

CCR2⁺ cells associate with perifibrotic regions in lungs of mice with bleomycin-induced fibrosis

CCR2⁺ cells are tightly linked with the development of lung fibrosis as indicated by studies in *Ccr2*^{-/-} mice, however the temporal and spatial nature of the CCR2⁺ cells and their progeny relative to fibrosis is not well described. To track CCR2⁺ cells types during development of bleomycin-induced fibrosis, we used a transgenic *Ccr2*^{gfp/+} knockin/knockout reporter mice harboring the enhanced green fluorescent protein (EGFP) sequence in the *Ccr2* gene. *Ccr2*^{gfp/+} and *Ccr2* null (*Ccr2*^{gfp/gfp}) mice were intranasally administered bleomycin as an established but imperfect model of IPF (28-30). In this model, inflammation rises on days 3 through 10 post-bleomycin, followed by the development of fibrosis over 14 to 28 days. Serial tissue sections were scored for EGFP-expressing cells and fibrosis in merged images (**Fig. 1A-C; Fig. S1**). Compared to control mice, the numbers of CCR2-EGFP⁺ cells in lung sections were significantly increased at 14 days after bleomycin delivery, then diminished at day 28 (**Fig. 1B**). CCR2-EGFP⁺ cell incidence mapped with fibrosis quantified by the modified Ashcroft score (31) (**Fig. 1C**). The abundance of CCR2-EGFP⁺ cells was relatively low in regions of both normal appearing lung and dense fibrosis. Instead, these cells were abundant in regions that surrounded the remodeled parenchyma and those areas near fibrosis, supportive of a role for CCR2⁺ cells in the fibrotic niche. At days 14 and 28 there was significantly greater accumulation of CCR2-EGFP⁺ cells at the highest Ashcroft scores (**Fig. 1C**).

Mass cytometry was used to characterize types of CCR2⁺ cells found in bleomycin-induced injury. A cocktail of 35 cell marker antibodies (**Table S1**) allowed for accurate classification of immune cell populations on a single cell basis, as identified previously in the bleomycin model (**Fig. 1D; Fig. S2A**) (32, 33). At baseline, low numbers of CCR2-EGFP⁺ cells (**Fig 1A,B**) with characteristic markers of monocytes, dendritic cells and rare lymphocytes were present. Following bleomycin delivery, the percentage of GFP⁺ myeloid cells markedly increased, in concert with CCR2⁺ inflammatory monocytes. At day 28 post bleomycin, interstitial macrophage, which are derived from CCR2⁺, Ly6C^{high} inflammatory monocytes (15, 32, 34), were the most abundant EGFP⁺

myeloid cells type (**Fig. 1D, E, Fig. S2B**). As expected, *Ccr2^{gfp/gfp}* mice lacked inflammatory monocytes and interstitial macrophages at day 0 and 28 (**Fig. S2B**). To confirm the observed shift in monocyte-to-macrophage cell types and further characterize the CCR2-expressing cells, we performed single cell RNA sequencing of the mouse lung at day 20 post-bleomycin, providing high precision of immune cell phenotypes, while agnostic to current surface markers (14, 15). In control lungs, *Ccr2* expression primarily clustered in a subset of monocyte-lineage cells that co-expressed inflammatory monocyte and dendritic cell genes (**Fig. 1F, G**). After bleomycin, *Ccr2*⁺ interstitial macrophages were enriched in genes previously associated with pro-fibrosis pathways in mouse models and human lung tissues, notably *Il-1b*, and *Spp1*, *Apoe*, *Mmp14*, and others (**Fig. 1G, S3**) (14-16, 19, 35). These results describe a temporal and spatial relationship of CCR2-expressing cells with the development of a fibrotic niche and are consistent with the reported role of CCR2⁺ cells in genetic models.

⁶⁴Cu-DOTA-ECL1i PET lung uptake is increased during bleomycin fibrosis

We have previously developed ⁶⁴Cu-DOTA-ECL1i to image CCR2⁺ cells by PET and reported the accuracy of this radiotracer uptake in preclinical models (24, 25, 27). As a next step, we examined ⁶⁴Cu-DOTA-ECL1i and PET/CT application in lung fibrosis using the bleomycin-injury mouse model. The uptake of radiotracer in the lungs of mice given bleomycin, compared to controls, showed minimal increase at day 2, with significant increase at day 14 (**Fig. 2A-D**). Uptake diminished at day 28, though remained significantly above control levels. The changes in PET signal were comparable to the relative abundance of CCR2⁺ cells detected by immunostaining at days 0, 14 and 28 (**Fig. 1B, Fig. 2D**). Molecular specificity of ⁶⁴Cu-DOTA-ECL1i for detection of CCR2⁺ cell burden was demonstrated by the significantly decreased uptake in *Ccr2^{gfp/gfp}* knockout mice compared to wild-type mice at day 14 (**Fig. 2B**). Radiotracer specificity was confirmed by decreased uptake in mice injected with non-radioactive ECL1i as competitive receptor blockade (**Fig. 2C**). To approximate the relationship of the ⁶⁴Cu-DOTA-ECL1i PET signal and regions of fibrotic remodeling, fixed lungs were sectioned through the coronal plane after scanning. Trichrome-stained lung sections aligned with the PET images showed prominent ⁶⁴Cu-DOTA-ECL1i uptake in regions of lung inflammation and fibrosis (**Fig. 2E**). The relationship of radiotracer uptake and fibrosis was consistent with an enrichment of CCR2-EGFP⁺ cells in perifibrotic regions of the lung. These data suggest that ⁶⁴Cu-DOTA-ECL1i PET uptake mirrors

regional differences in CCR2⁺ cell recruitment during inflammation and the progression of fibrosis.

⁶⁴Cu-DOTA-ECL1i PET uptake is increased in the lungs of mice with radiation-induced fibrosis

Although the responses of monocytes and macrophages in bleomycin-induced fibrosis have been extensively characterized, the subacute, high-inflammatory condition could bias immune cell populations. As an alternative, we examined ⁶⁴Cu-DOTA-ECL1i PET lung activity in a mouse model of radiation-induced injury and fibrosis. Radiation injury is a chronic, indolent process that is accompanied by inflammatory monocytes and interstitial macrophages, increased IL-1 β , and mitigated by genetic deletion of *Ccr2* or *Il-1b* in mice (13, 36). We ascertained ⁶⁴Cu-DOTA-ECL1i PET uptake in mice after receiving focused, right-lung irradiation with the non-irradiation left lung assigned as a control (**Fig. S4A**). At 14 and 26 weeks after irradiation, radiotracer uptake was significantly increased in the right lung, while little was detected in the left (**Fig. S4B-D**). Similar to the bleomycin fibrosis model, the ⁶⁴Cu-DOTA-ECL1i PET signal was present in regions of fibrotic remodeling, as indicated by alignment of whole lung preparations stained with trichrome with the PET images (**Fig. S4B, C**). At 14 and 26 weeks, there were significantly more CCR2⁺ cells in the irradiated right compared to control left lung (**Fig. S4E**). The findings are consistent with the known *Ccr2*-dependent responses in radiation-induced fibrosis.

IL-1 β blockade of bleomycin-induced fibrosis decreases ⁶⁴Cu-DOTA-ECL1i PET uptake

As a viable clinical marker, ⁶⁴Cu-DOTA-ECL1i PET should also detect a therapeutic modulation of CCR2⁺ inflammatory and pro-fibrotic processes. IL-1 β is a proinflammatory cytokine produced by the inflammasome and active in lung fibrosis (19, 37). IL-1 β is induced by lung delivery of profibrotic agents, can induce fibrosis upon delivery to the mouse airway, and activates CCL2-mediated chemotaxis, leading to increased lung interstitial macrophages (19, 37-39). Genetic deficiency of the IL-1 axis reduces inflammation following bleomycin injury (38, 39). As expected, interstitial macrophages expressed IL-1 β in the bleomycin model (**Fig. S3**). We sought to determine if the bleomycin pro-fibrotic inflammatory process could be interrupted during late inflammation and this response imaged using ⁶⁴Cu-DOTA-ECL1i PET. Mice receiving bleomycin were treated with IgG isotype control or monoclonal antibody against IL-1 β from days 10 through 28, a treatment schedule advised for testing antifibrotic therapies in preclinical models (40) (**Fig.**

3A). Compared to controls, lung fibrosis was decreased by anti-IL-1 β antibody treatment at day 28 (**Fig. 3B,C**). Lung expression of *Ccr2*⁺ cells was also reduced, as detected by mRNA in situ hybridization (**Fig. 3D,E**). In parallel, ⁶⁴Cu-DOTA-ECL1i PET uptake in the lungs of IL-1 β antibody treated mice was significantly reduced (**Fig. 3F, G**).

Pirfenidone treatment of bleomycin-induced fibrosis decreases ⁶⁴Cu-DOTA-ECL1i PET uptake

While anti-IL-1 β antibodies are not a standard IPF treatment, pirfenidone is one of two drugs approved for patients (3). Pirfenidone treatment is reported to reduce fibrosis in bleomycin-, radiation-, and graft-versus-host-induced lung fibrosis models (22, 23, 41, 42). Thus, we examined pirfenidone modulation of lung ⁶⁴Cu-DOTA-ECL1i PET uptake. Mice were given pirfenidone in chow (43) on days 10 through 28 following bleomycin administration (**Fig. 3H**). Compared to mice fed chow only, pirfenidone treatment decreased lung fibrosis (**Fig. 3I, J**), the accumulation of *Ccr2*⁺ cells (**Fig. 3K**), and interstitial macrophages (**Fig. 3L**). The treatment effect on CCR2⁺ cell signal was detected as a decrease in ⁶⁴Cu-DOTA-ECL1i PET uptake (**Fig. 3M, N**). These observations indicate that ⁶⁴Cu-DOTA-ECL1i PET can detect changes in CCR2⁺ cells associated with fibrosis and suggest the potential of the PET tracer to monitor therapeutic response in IPF patients or to pre-screen patients for a specific drug treatment.

CCR2⁺ cells are increased in human fibrotic lung disease

Elevated levels of inflammatory monocytes and tissue/interstitial macrophages are also found in lung tissues of patients with IPF and described by transcriptional profiles (14, 15, 21, 44, 45). Characterizing the regional distribution of CCR2⁺ monocytes and macrophages in affected human lung is essential for the clinical application of ⁶⁴Cu-DOTA-ECL1i PET. Certainly, assessing regional differences of CCR2⁺ cellular activity in patients with newly diagnosed or progressive IPF by histology is not feasible. We therefore examined CCR2 expression in lungs removed from patients with end-stage pulmonary fibrosis at lung transplantation (n=11) (**Table S2**) and compared these regions to pre-transplant chest CT images performed for standard clinical evaluation of some subjects. Samples were obtained from regions that included the pleural surface, or within 2 to 5 cm of the pleural edge, using our research protocol for tissue procurement (24), which allows mapping and alignment of biopsied regions to chest CT (e.g., samples from the upper lobe, superior segment of the lower lobe). CCR2⁺ cells in lung tissues were identified by

immunofluorescent staining of fibrotic tissues and compared to non-fibrotic lungs that were donated but unsuitable for transplantation (control lungs, n=4). Serial sections processed by trichrome staining were used to determine the location of CCR2⁺ cells relative to fibrotic remodeling. CCR2⁺ cells were most abundant in lung tissue sections from subjects with fibrosis compared to no fibrosis (**Fig. 4A, B, C, D**). As in the bleomycin mouse models, CCR2⁺ cells were elevated in cellular regions adjacent to highly fibrotic regions (**Fig. 4A, Fig. S5**), suggesting that regions of high CCR2⁺ cell expression precede the development of fibrotic scar. Mass cytometry was also used to profile CCR2⁺ cell phenotypes in lung biopsies from regions adjacent to the histology sections. In non-fibrotic control lung tissues, CCR2⁺ cells in non-fibrotic lung tissue were primarily CD14⁺, CD16⁻ inflammatory monocytes, as could be predicted in lungs from donors on recent mechanical ventilation (**Fig. S6**). By comparison, there were fewer inflammatory monocytes in the fibrotic lung tissue relative to significant increase in the percent of interstitial macrophages (**Fig. 4E, Fig. S6**).

⁶⁴Cu-DOTA-ECL1i uptake is increased in ex vivo lung tissues of subjects with fibrosis

Toward translation to human disease, we next determined if ⁶⁴Cu-DOTA-ECL1i recognized CCR2 in human fibrotic lung tissue (**Table S2**). Lung tissues immunostained for CCR2 were compared to serial sections assayed for ⁶⁴Cu-DOTA-ECL1i by autoradiography (**Fig. 4F, Fig. S7**). Radiotracer specificity was shown by loss of activity in tissues treated with excess non-radioactive ECL1i. Photomicrographs of tissue sections analyzed for CCR2 by immunofluorescent staining and autoradiography were overlaid. Zones of high and low activity of CCR2 staining were compared to ⁶⁴Cu-DOTA-ECL1i binding (**Fig. 4G, Fig. S7**). Although the signal from ⁶⁴Cu autoradiography is lower resolution compared to the high resolution of immunofluorescent microscopy, regional differences in signal were highly concordant. Collectively, the data indicate that CCR2⁺ cells regionally associate with areas of fibrosis in human lung and can be detected ex vivo by ⁶⁴Cu-DOTA-ECL1i.

⁶⁴Cu-DOTA-ECL1i PET dosimetry in healthy volunteers

Lung CCR2⁺ cell monitoring may be a valuable clinical tool for the management of patients with pulmonary fibrosis, particularly given the small number of targetable molecular lung markers available. Thus, we obtained approval for use of ⁶⁴Cu-DOTA-ECL1i in humans. The primary aim

of this Phase 0/I study was to establish the safety of ^{64}Cu -DOTA-ECL1i, to obtain initial estimates of the radiation dosimetry, and to assess lung retention for this marker. Six healthy adult volunteers (3 males, 3 females) with normal lung function were examined (**Table S3**, see human protocol in **Supplementary Methods**). Following intravenous injection of 185 to 370 MBq of ^{64}Cu -DOTA-ECL1i, subjects underwent whole body PET/CT scans acquired over about 60 minutes each. Serial PET images were acquired at approximately 30-90 minutes; 2-3 hours; 18-24 hours; and 40-44 hours post injection. Each PET scan was accompanied by a low-dose CT scan for PET attenuation correction. Analysis of images for dosimetry demonstrated minimal lung uptake and predominantly renal clearance (**Fig. 5A**, **Table S4**). Clearance of ^{64}Cu -DOTA-ECL1i from blood was very rapid (**Fig. 5B**). Renal clearance was estimated using urine and bladder activity as a surrogate (**Fig. 5C**). Dosimetry showed the urinary bladder wall as the dose-limiting organ, but overall reasonable dosimetry (**Table S4**). No observable clinically adverse effects of ^{64}Cu -DOTA-ECL1i were identified. Low lung uptake and acceptable levels of radiation exposure led us to next evaluate uptake of ^{64}Cu -DOTA-ECL1i in the lungs of subjects with pulmonary fibrosis.

^{64}Cu -DOTA-ECL1i PET activity is increased in lungs of patients with IPF

Four subjects with IPF underwent ^{64}Cu -DOTA-ECL1i PET/CT imaging (**Fig. 6**, **Table S3**). The pulmonary function testing (FVC) and chest CT features integrated into a fibrotic lung disease score (46) that varied among the subjects evaluated (**Table 1**). Subjects with IPF, and an additional healthy volunteer, underwent dynamic PET imaging of the chest for 60 minutes, beginning at the time of intravenous injection of 296 to 370 MBq of ^{64}Cu -DOTA-ECL1i. The scan was followed by whole-body images obtained 80-90 minutes post-injection and a chest CT. Compared to lung uptake in the healthy volunteer, uptake was increased in IPF patients and enhanced in regions of reticulation and honeycomb patterns, consistent with localization of ^{64}Cu -DOTA-ECL1i uptake in areas of active fibrotic remodeling. In most cases, radiotracer uptake was greatest in subpleural regions of the lung observed in sagittal sections and posterior coronal sections providing a spectrum of ^{64}Cu -DOTA-ECL1i lung uptake (**Fig. 6A, B**). Whole-body images at 80-90 min post-injection showed less prominent uptake than the dynamic images due to rapid radiotracer clearance and metabolism, indicating that imaging during the first 60 minutes post-injection was superior for quantification.

^{64}Cu -DOTA-ECL1i PET lung scans from the subjects were analyzed for standardized uptake value (SUV) and maximum SUV (SUVmax) (**Table 1**). Logan plots were used to determine the distribution volume (DV) using parametric maps derived from the dynamic images (47) and compared to that in healthy lungs (**Fig. 6C, Fig. S8**). The pulmonary artery was used as the blood reference region and high-uptake regions from sagittal and transverse images that best isolated vascular from parenchymal structures were selected for these assessments. Logan plots confirmed the increased uptake of radiotracer in areas of fibrosis, independent of blood flow. The average DV of the fibrotic regions (0.60 ± 0.04 , $n=4$) was more than twice that of non-fibrotic regions (0.28 ± 0.04 , $n=4$, $p<0.05$) (**Fig. 6D**). The SUVmax in these same fibrotic regions also tracked with distribution volume, validating the use of SUV. Metabolite analyses of blood samples obtained at 2-3 hours post-injection identified the major radioactive species as intact tracer (20-40%), free ^{64}Cu (55-75%), which is not taken up in lungs (48), and negligible ^{64}Cu -associated proteins (<5%). Thus, metabolites were unlikely to interfere with interpreting ^{64}Cu -DOTA-ECL1i uptake as a measure of CCR2 expression. By these established measures of lung activity, two subjects had notably high uptake (IPF3, IPF4) compared to the two others (IPF1, IPF2). A subject who required oxygen supplementation (IPF4) had the highest ^{64}Cu -DOTA-ECL1i uptake when compared to areas of similarly severe fibrosis identified in the other subjects (**Table 1**). The subject with the highest ratio of SUV or DV to fibrosis score (IPF2) developed rapid progression of disease, leading to lung transplantation. Moreover, assessment of coronal images showed differences in overall PET uptake between different subjects (**Fig. 6B**). This small number of patients was insufficient to define radiotracer uptake, fibrosis, and lung function relationships. However, these findings suggest that ^{64}Cu -DOTA-ECL1i uptake may represent an important determinant of disease activity.

Discussion

The nature of lung injury in IPF is not well defined and may be triggered by cell death or senescence (1, 19, 37). Nevertheless, for over two decades, the inflammatory response associated with fibrosis has been linked to bone marrow-derived CCR2⁺ lung monocytes and interstitial macrophages in animal models (11-13, 49). Most recently, analysis of lung cells from subjects with IPF using single cell transcriptional profiling has placed the interstitial macrophage in the profibrotic “niche”, serving as a driver for pulmonary fibrosis (10, 15, 16, 21, 45). Here, we

complement those studies by showing a consistent, temporal, and spatial relationship between CCR2⁺ interstitial monocytes/macrophages and fibrotic regions using preclinical models and human tissue. We then extend those findings by showing the feasibility of a non-invasive PET imaging strategy for detection of CCR2⁺ lung cells during inflammation in the same preclinical models. Finally, we advance the potential to detect CCR2⁺ lung cells in patients by demonstrating perifibrotic uptake in first-in-human ⁶⁴Cu-DOTA-ECL1i PET imaging in subjects with IPF. Our observations introduce the possibility that the inflammatory profibrotic niche may be non-invasively imaged in human fibrotic lung disease. The findings lead us to propose that measurable activity detected by ⁶⁴Cu-DOTA-ECL1i PET may be used as a biomarker of immune cell activity in IPF.

Consideration of CCR2⁺ cells as a marker of profibrotic disease activity in the lung was judged by cellular activity following bleomycin injury, imaged at high resolution using CCR2-EGFP and *Ccr2* in situ hybridization, which localized to the perifibrotic region (**Figs. 1A, 3D**). The pattern was most striking in human tissues where CCR2⁺ cells were organized in distinct cell infiltrates around regions of marked fibrosis (**Figs. 4A, S5**). We found that CCR2⁺ interstitial macrophages in our model expressed the profibrotic genes, including *Cx3cr1*, identified by others in mouse models and human fibrotic lungs (*10, 14-16, 21, 45*) (**Figs. 1G, S3**). Our localization of the interstitial macrophages was consistent to photomicrographs in prior reports; *Cx3cr1*-expressing cells were directly adjacent to fibroblasts in the bleomycin model (*14*) and MERTK⁺ interstitial macrophages surround fibroblastic foci in human lung tissues (*21*). By scanning large regions of CCR2-immunostained tissue in human tissues, we could identify particularly dense CCR2⁺ infiltrates surrounding areas of honeycomb and scar, often in a “penumbra”-like pattern, suggesting a leading edge of CCR2⁺ cells driving the fibrotic process.

⁶⁴Cu-DOTA-ECL1i uptake in tissue by autoradiography was also highly correlated with regions of CCR2 immunostaining, providing a level of validation for imaging of human subjects (**Figs. 4F, S7**). Ultimately, by using PET/CT, we found that patients with IPF had the most prominent signal in the subpleural regions. In limited studies, we linked the abundance of CCR2⁺ cells in regions of tissue from explanted lungs to the pre-transplant CT scans of those same regions (**Figs. 4A, S5**). However, in our small cohort of IPF subjects who underwent PET imaging, uptake was

sometimes observed in regions without radiographic fibrosis. The signal in non-fibrotic lung may mark tissue in jeopardy of remodeling, hinting that ^{64}Cu -DOTA-ECL1i PET could be a clinical tool for risk assessment (**Fig. 6**). We plan more rigorous validation of ^{64}Cu -DOTA-ECL1i PET in patients with IPF undergoing lung transplantation, using explanted fibrotic lungs for comprehensive analysis of CCR2 levels and gene expression in specific anatomic locations, as guided by PET/CT.

It was essential we demonstrate that ^{64}Cu -DOTA-ECL1i PET could detect changes in CCR2⁺ populations in treatment models. Modulation of CCR2 accumulation using IL-1 β blockade and pirfenidone each significantly decreased PET radiotracer uptake. Previously it was shown that anti-IL-1 β antibody blockade or genetic deficiency interrupts lung CCL2, egress of CCR2⁺ cells, and fibrosis (19, 37, 38). Indeed, even our treatment later in the course of inflammation (day 10 post bleomycin) showed effective diminution of CCR2⁺ cells and fibrosis, accompanied by decreased ^{64}Cu -DOTA-ECL1i PET uptake. The treatment raises consideration for the use of monoclonal antibody against human IL-1 β (canakinumab), or the IL-1R antagonist, anakinra, in IPF. A more clinically relevant approach was the treatment of bleomycin-induced fibrosis using pirfenidone, which reduced lung fibrosis, as previously reported (23, 41). A parallel fall in the burden of Ccr2⁺ cells was accompanied by decreased ^{64}Cu -DOTA-ECL1i PET uptake. Although studied for many years, the precise pharmacology of pirfenidone has not been defined. At least one study using bleomycin injury reported a decrease in lung macrophages, CCL2, and CCR2 (23). Interestingly, pirfenidone inhibited NLRP3 inflammasome activation and IL-1 β production in endotoxin-mediated lung injury of mice (50) pointing to the inflammasome as one pharmacologic target. Regardless, we now identify a potential drug whose effects may be reported by PET imaging with our non-invasive radiotracer.

There are unique, comparative advantages of ^{64}Cu -DOTA-ECL1i PET uptake as a biomarker of IPF disease activity. As noted, chest imaging by high resolution CT scan is the current standard for diagnosis and a predictor of survival (5, 6), but it cannot yet be used to target a specific class of drug therapy. ^{18}F -Fluorodeoxyglucose (^{18}F -FDG)-PET can distinguish patients with severe IPF (51). However, ^{18}F -FDG uptake is a non-specific marker of inflammation without a distinct molecular target. Newer PET radiotracers that measure $\alpha_v\beta_6$ integrin (52), cathepsin (53), and

collagen synthesis (54) may have related molecular phenotypes to provide complementary or alternative approaches to ^{64}Cu -DOTA-ECL1i PET. Another feature of ^{64}Cu -DOTA-ECL1i is the selection of Cu-64 as the radiolabel, which provides high specific activity and has straightforward radiochemistry. The stability and half-life of ^{64}Cu ($t_{1/2}=12.7\text{h}$) makes possible shipping of ^{64}Cu -DOTA-ECL1i for future multicenter trials.

This study has limitations. First, therapeutic studies in mice are restricted to a few established experimental models with well-characterized trajectories and endpoints (30). Like most mouse models, bleomycin-induced fibrosis does not recapitulate all features of human disease, however, similar monocyte and macrophage populations are present after bleomycin and in IPF (14, 15). Second, CCR2^+ monocytes/macrophages are but one inflammatory cell type identified in pulmonary fibrosis, and consideration for therapeutic depletion of this population may leave another pathogenic pro-fibrotic cell exposed to drive fibrosis or reveal a role of CCR2^+ cells to resolve fibrosis (55). Third, as a first-in-human use of the radiotracer, a restricted number of subjects have been studied. We currently lack sufficient numbers of patients to draw firm conclusions related to the spectrum of lung uptake or relationship to therapy. We estimate that a sample size of 40 subjects with IPF would be required to achieve a 90% power to detect a significant correlation between ^{64}Cu -DOTA-ECL1i uptake and whole-lung fibrosis score. Finally, although we have suggested that the effects of pirfenidone may be monitored by ^{64}Cu -DOTA-ECL1i PET, it is possible that we will not observe the same effects in patients diagnosed late in the course of disease.

We conclude that detailed cellular tracking and lung localization of CCR2^+ cells during the profibrotic processes expands knowledge of the role of these cells in pulmonary fibrosis, while development of a cell-targeted imaging probe may enhance clinical assessment of patients with IPF. The availability of ^{64}Cu -DOTA-ECL1i PET as a cell-specific biomarker raises the distinct possibility that patients with IPF or other fibrotic diseases could be identified by quantitative CCR2^+ measurement for specific drug treatment choices. Future studies may determine if ^{64}Cu -DOTA-ECL1i PET can monitor pirfenidone therapy. At this time, it is unknown how the other approved anti-fibrotic agent, nintedanib, impacts the accumulation of CCR2^+ cells or ^{64}Cu -DOTA-ECL1i PET uptake. However, advancing the development of one of the many CCR2 antagonists

that have been used in clinical trials (56, 57) may be an additional direction for targeted therapy to control a high CCR2⁺ cell condition. Future studies of ⁶⁴Cu-DOTA-ECL1i PET as a broader tool for assessing inflammatory cell activity, and adapting it for fibrosis in other organs, such as the liver, which also share high CCR2⁺ cell populations (58).

Materials and Methods

Study design

The objective of these studies was to demonstrate the feasibility of the PET radiotracer ⁶⁴Cu-DOTA-ECL1i to detect CCR2⁺ cells in patients with pulmonary fibrosis as a means to follow disease activity and for cell-targeted drug therapy. CCR2⁺ monocytes and interstitial macrophages were chosen as a target by reason of the pathologic roles in fibrosis of CCR2⁺ monocytes and lung interstitial macrophages in pulmonary fibrosis (10, 14-20). Complementary in vivo mouse and ex vivo human studies were designed with the goal of translating ⁶⁴Cu-DOTA-ECL1i PET imaging to humans. The CCR2⁺ cell populations were localized relative to fibrotic regions in mouse lung tissues and characterized using a CCR2-reporter strain, single cell mass cytometry, *Ccr2* RNA in situ hybridization, and single cell transcriptomics (see Supplementary Methods), in parallel with ⁶⁴Cu-DOTA-ECL1i PET uptake. Two mouse fibrosis models were used that are CCR2-dependent: the established bleomycin-induced fibrosis model and chronic radiation lung injury (13, 36). To determine if the ⁶⁴Cu-DOTA-ECL1i PET uptake indicated modulation of CCR2⁺ monocytes and macrophage populations, therapeutic interventions were performed in the bleomycin injury model at the approximate onset of the fibrotic process, on day 10, and continued through 28, as recommended by a panel of experts (40). To modulate the proinflammatory effects of interstitial macrophages, both IL-1 β blocking antibody and a clinically relevant medication, pirfenidone, were used. In each intervention, control and treated groups were assessed for fibrosis, CCR2⁺ cell abundance and location, imaged by ⁶⁴Cu-DOTA-ECL1i PET. All animal studies were approved by the Institutional Animal Care and Use Committee at Washington University.

Ex vivo studies in human lung tissues explanted from subjects with IPF undergoing lung transplantation were designed to support the validity of in vivo imaging of subjects with IPF, and to localize CCR2⁺ cells relative to fibrotic regions. Donor lungs obtained from subjects without fibrosis that were unsuited for transplantation were used as a control. CCR2⁺ cells detected by

immunofluorescence were associated with regions of fibrosis and correlation with the uptake of ^{64}Cu -DOTA-ECL1i as detected by autoradiography in serial tissue samples. The primary objectives of the human in vivo studies were to determine dosimetry and safety of ^{64}Cu -DOTA-ECL1i for PET imaging and detect uptake of radiotracer in the lung. ^{64}Cu -DOTA-ECL1i was prepared for human imaging as described (24), under exploratory investigational new drug permission, using good manufacturing practices (see Supplementary Materials). Healthy volunteers included active cigarette smokers and never-smokers; all had normal lung spirometry testing and no diseases or medication use. Subjects were diagnosed with IPF by clinicians at the Washington University Interstitial Lung Disease Clinic, according to consensus clinical criteria (5, 6). The uptake of ^{64}Cu -DOTA-ECL1i in lungs was measured in PET images using the method of Logan (47) and compared to clinical measures of lung function and a fibrosis score (46). Approval for human studies was provided by the Institutional Review Board at Washington University (IRB# 201606004), the Institutional Radioactive Drug Research Committee (protocol 826L) and the Food and Drug Administration (IND 137620). Written consent was obtained from all study participants.

Mouse models. For the bleomycin-induced fibrosis model, male and female C57BL/6J wild-type mice (age, 8-10 weeks; approximately 25 grams; Jackson Labs) or mice with an EGFP-encoding DNA fragment inserted at the translation start site of *Ccr2* (B6C-Ccr2^{tm1.1Cln/J}, #027619; Jackson Labs; referred to as CCR2^{GFP/+}) were administered a single dose of bleomycin (Sigma), 3 U/kg, intranasal. For the single cell RNA sequencing studies, bleomycin oropharyngeal aspiration of 2 U/kg, was used. Co-housed, naïve mice served as controls to avoid confusing inflammatory responses induced by airway administration of saline vehicle. Weights were obtained every 1 to 3 days. Some mice given bleomycin were treated with isotype matched, polyclonal Armenian hamster IgG or anti-IL-1 β (both from Bio X Cell), injected intraperitoneally, 200 μg , three times per week (59). Other cohorts were treated with pirfenidone (eEnovation Chemicals, D404655) mixed with rodent chow at 0.5% by weight, available ad libitum, as described (43). Lung radiation injury leading to fibrosis was induced in CD-1 mice (female, 5-7 weeks, 22-24 grams; Charles Rivers). A focal region of the right lung was irradiated with 20 Gy (60) delivered by the Small Animal Radiation Research Platform (Xstrahl).

Mouse PET/CT and image analysis. Dynamic PET and CT scans were acquired using Inveon microPET/CT (Siemens) or Focus 220 PET (Concorde Microsystems) scanners, at 45 through 60 minutes following tail vein injection of ^{64}Cu -DOTA-ECL1i (3.7 MBq per mouse). PET images were corrected for attenuation, scatter, normalization, and camera dead time, and co-registered with CT images. Both PET scanners were routinely cross-calibrated. The PET images were reconstructed with the maximum a posteriori algorithm and the organ uptake calculated as percent injected dose per gram (%ID/g) of tissue in three-dimensional regions of interest (ROIs) without correction for partial volume effect, using Inveon Research Workplace software (Siemens). Competitive PET blocking studies were performed with co-injection of non-radiolabeled ECL1i and ^{64}Cu -DOTA-ECL1i at a molar ratio of 500:1 prior to imaging.

Human PET/CT, imaging and dosimetry. (see Supplementary methods for human protocol and dosimetry details). Healthy volunteers received intravenous injection of 185-370 MBq of ^{64}Cu -DOTA-ECL1i followed by four PET/CT scans (Biograph 40 PET/CT, Siemens) at 1 to 42 h. Images were acquired from the top of the skull through mid-thigh. Subjects with pulmonary fibrosis underwent a dynamic (0-60 minutes) PET scan of the thorax, which commenced upon intravenous injection of 296-370 MBq of ^{64}Cu -DOTA-ECL1i and was followed by whole-body PET/CT imaging at 80-90 minutes post-injection. Dosimetry was calculated as previously described (61). Briefly, regions of interest (ROIs) were placed over the major organs using the CT as a guide. The time-activity curves were determined using all scans obtained to measure organ residence times. These data, plus the gamma radiation activity of urine collected after tracer injection, were used to calculate the dosimetry with OLINDA/EXM software (62). Organ SUV at each time point was determined directly from the images.

Statistical analysis. Statistical analysis was performed using GraphPad Prism (Version 6.07). Differences between two groups were compared using the Mann-Whitney U test. Multiple medians were compared using the Kruskal-Wallis test followed by Dunn's Multiple Comparison. Paired comparisons were analyzed using the Wilcoxon Signed Rank test. The Spearman correlation was used for analysis of ex vivo human tissue samples. $P < 0.05$ was indicative of a statistically significant difference. Box plots show the median, a box representing first and third quartiles, and whiskers at 5th and 95th percentile, unless otherwise stated.

Acknowledgments: We thank the study subjects for participation, and Luigi Adamo and Douglas Mann for assistance with pirfenidone dosing. **Funding:** NIH R01 HL131908 (SLB, YL) and R35 HL145212 (YL), SLB is the D. and H. Moog Professor of Pulmonary Medicine. Tissue scanning was performed in the Hope Center Alafi Neuroimaging Lab supported by the P30 NS057105 Neuroscience Blueprint Interdisciplinary Center Core award to Washington University. **Conflicting interests:** S.L. Brody, D. Kreisel, K.J. Lavine, C. Combadiere, R.J. Gropler, and Y. Liu have a pending patent entitled “Compositions and Methods for Detecting CCR2 Receptors” (application number 15/611,577). The other authors report no conflicts. **Data and materials available:** Single cell sequencing data will be deposited in NCBI GEO upon publication.

References and Notes

1. F. J. Martinez, H. R. Collard, A. Pardo, G. Raghu, L. Richeldi, M. Selman, J. J. Swigris, H. Taniguchi, A. U. Wells, Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers* **3**, 17074 (2017).
2. J. Hutchinson, A. Fogarty, R. Hubbard, T. McKeever, Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. *Eur Respir J* **46**, 795-806 (2015).
3. T. E. King, Jr., W. Z. Bradford, S. Castro-Bernardini, E. A. Fagan, I. Glaspole, M. K. Glassberg, E. Gorina, P. M. Hopkins, D. Kardatzke, L. Lancaster, D. J. Lederer, S. D. Nathan, C. A. Pereira, S. A. Sahn, R. Sussman, J. J. Swigris, P. W. Noble, A. S. Group, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* **370**, 2083-2092 (2014).
4. L. Richeldi, R. M. du Bois, G. Raghu, A. Azuma, K. K. Brown, U. Costabel, V. Cottin, K. R. Flaherty, D. M. Hansell, Y. Inoue, D. S. Kim, M. Kolb, A. G. Nicholson, P. W. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard, S. Stowasser, R. Schlenker-Herceg, B. Disse, H. R. Collard, I. T. Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* **370**, 2071-2082 (2014).
5. D. A. Lynch, N. Sverzellati, W. D. Travis, K. K. Brown, T. V. Colby, J. R. Galvin, J. G. Goldin, D. M. Hansell, Y. Inoue, T. Johkoh, A. G. Nicholson, S. L. Knight, S. Raoof, L. Richeldi, C. J. Ryerson, J. H. Ryu, A. U. Wells, Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* **6**, 138-153 (2018).
6. G. Raghu, M. Remy-Jardin, J. L. Myers, L. Richeldi, C. J. Ryerson, D. J. Lederer, J. Behr, V. Cottin, S. K. Danoff, F. Morell, K. R. Flaherty, A. Wells, F. J. Martinez, A. Azuma, T. J. Bice, D. Bouros, K. K. Brown, H. R. Collard, A. Duggal, L. Galvin, Y. Inoue, R. G. Jenkins, T. Johkoh, E. A. Kazerooni, M. Kitaichi, S. L. Knight, G. Mansour, A. G. Nicholson, S. N. J. Pipavath, I. Buendia-Roldan, M. Selman, W. D. Travis, S. Walsh, K. C. Wilson, E. R. S. J. R. S. American Thoracic Society, S. Latin American Thoracic, Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* **198**, e44-e68 (2018).
7. M. K. D. Scott, K. Quinn, Q. Li, R. Carroll, H. Warsinske, F. Vallania, S. Chen, M. A. Carns, K. Aren, J. Sun, K. Koloms, J. Lee, J. Baral, J. Kropski, H. Zhao, E. Herzog, F. J. Martinez, B. B. Moore, M. Hinchcliff, J. Denny, N. Kaminski, J. D. Herazo-Maya, N. H. Shah, P. Khatri, Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. *Lancet Respir Med* **7**, 497-508 (2019).
8. M. O. Paterniti, Y. Bi, D. Rekić, Y. Wang, B. A. Karimi-Shah, B. A. Chowdhury, Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. *Ann Am Thorac Soc* **14**, 1395-1402 (2017).
9. N. V. Serbina, E. G. Pamer, Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol* **7**, 311-317 (2006).
10. M. A. Gibbons, A. C. MacKinnon, P. Ramachandran, K. Dhaliwal, R. Duffin, A. T. Phythian-Adams, N. van Rooijen, C. Haslett, S. E. Howie, A. J. Simpson, N. Hirani, J. Gauldie, J. P. Iredale, T. Sethi, S. J. Forbes, Ly6Chi monocytes direct alternatively

- activated profibrotic macrophage regulation of lung fibrosis. *Am J Respir Crit Care Med* **184**, 569-581 (2011).
11. B. B. Moore, R. Paine, 3rd, P. J. Christensen, T. A. Moore, S. Sitterding, R. Ngan, C. A. Wilke, W. A. Kuziel, G. B. Toews, Protection from pulmonary fibrosis in the absence of CCR2 signaling. *J Immunol* **167**, 4368-4377 (2001).
12. M. Gharaee-Kermani, R. E. McCullumsmith, I. F. Charo, S. L. Kunkel, S. H. Phan, CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. *Cytokine* **24**, 266-276 (2003).
13. A. M. Groves, C. J. Johnston, J. P. Williams, J. N. Finkelstein, Role of Infiltrating Monocytes in the Development of Radiation-Induced Pulmonary Fibrosis. *Radiat Res* **189**, 300-311 (2018).
14. D. Aran, A. P. Looney, L. Liu, E. Wu, V. Fong, A. Hsu, S. Chak, R. P. Naikawadi, P. J. Wolters, A. R. Abate, A. J. Butte, M. Bhattacharya, Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).
15. A. V. Misharin, L. Morales-Nebreda, P. A. Reyfman, C. M. Cuda, J. M. Walter, A. C. McQuattie-Pimentel, C. I. Chen, K. R. Anekalla, N. Joshi, K. J. N. Williams, H. Abdala-Valencia, T. J. Yacoub, M. Chi, S. Chiu, F. J. Gonzalez-Gonzalez, K. Gates, A. P. Lam, T. T. Nicholson, P. J. Homan, S. Soberanes, S. Dominguez, V. K. Morgan, R. Saber, A. Shaffer, M. Hinchcliff, S. A. Marshall, A. Bharat, S. Berdnikovs, S. M. Bhorade, E. T. Bartom, R. I. Morimoto, W. E. Balch, J. I. Sznajder, N. S. Chandel, G. M. Mutlu, M. Jain, C. J. Gottardi, B. D. Singer, K. M. Ridge, N. Bagheri, A. Shilatifard, G. R. S. Budinger, H. Perlman, Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. *J Exp Med* **214**, 2387-2404 (2017).
16. P. A. Reyfman, J. M. Walter, N. Joshi, K. R. Anekalla, A. C. McQuattie-Pimentel, S. Chiu, R. Fernandez, M. Akbarpour, C. I. Chen, Z. Ren, R. Verma, H. Abdala-Valencia, K. Nam, M. Chi, S. Han, F. J. Gonzalez-Gonzalez, S. Soberanes, S. Watanabe, K. J. N. Williams, A. S. Flozak, T. T. Nicholson, V. K. Morgan, D. R. Winter, M. Hinchcliff, C. L. Hrusch, R. D. Guzy, C. A. Bonham, A. I. Sperling, R. Bag, R. B. Hamanaka, G. M. Mutlu, A. V. Yeldandi, S. A. Marshall, A. Shilatifard, L. A. N. Amaral, H. Perlman, J. I. Sznajder, A. C. Argento, C. T. Gillespie, J. Dematte, M. Jain, B. D. Singer, K. M. Ridge, A. P. Lam, A. Bharat, S. M. Bhorade, C. J. Gottardi, G. R. S. Budinger, A. V. Misharin, Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med*, (2018).
17. T. Nouno, M. Okamoto, K. Ohnishi, S. Kaieda, M. Tominaga, Y. Zaizen, M. Ichiki, S. Momosaki, M. Nakamura, K. Fujimoto, J. Fukuoka, S. Shimizu, Y. Komohara, T. Hoshino, Elevation of pulmonary CD163(+) and CD204(+) macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. *J Thorac Dis* **11**, 4005-4017 (2019).
18. A. Lebrun, S. Lo Re, M. Chantry, X. Izquierdo Carrera, F. Uwambayinema, D. Ricci, R. Devosse, S. Ibouaaden, L. Brombin, M. Palmai-Pallag, Y. Yakoub, M. Pasparakis, D. Lison, F. Huaux, CCR2(+) monocytic myeloid-derived suppressor cells (M-MDSCs) inhibit collagen degradation and promote lung fibrosis by producing transforming growth factor-beta1. *J Pathol* **243**, 320-330 (2017).
19. H. W. Stout-Delgado, S. J. Cho, S. G. Chu, D. N. Mitzel, J. Villalba, S. El-Chemaly, S. W. Ryter, A. M. Choi, I. O. Rosas, Age-Dependent Susceptibility to Pulmonary Fibrosis Is

- Associated with NLRP3 Inflammasome Activation. *Am J Respir Cell Mol Biol* **55**, 252-263 (2016).
20. A. L. McCubrey, L. Barthel, M. P. Mohning, E. F. Redente, K. J. Mould, S. M. Thomas, S. M. Leach, T. Danhorn, S. L. Gibbings, C. V. Jakubzick, P. M. Henson, W. J. Janssen, Deletion of c-FLIP from CD11b(hi) Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. *Am J Respir Cell Mol Biol* **58**, 66-78 (2018).
21. C. Morse, T. Tabib, J. Sembrat, K. L. Buschur, H. T. Bittar, E. Valenzi, Y. Jiang, D. J. Kass, K. Gibson, W. Chen, A. Mora, P. V. Benos, M. Rojas, R. Lafyatis, Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. *Eur Respir J* **54**, (2019).
22. J. Du, K. Paz, R. Flynn, A. Vulic, T. M. Robinson, K. E. Lineburg, K. A. Alexander, J. Meng, S. Roy, A. Panoskaltsis-Mortari, M. Loschi, G. R. Hill, J. S. Serody, I. Maillard, D. Miklos, J. Koreth, C. S. Cutler, J. H. Antin, J. Ritz, K. P. MacDonald, T. W. Schacker, L. Luznik, B. R. Blazar, Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production. *Blood* **129**, 2570-2580 (2017).
23. M. Inomata, K. Kamio, A. Azuma, K. Matsuda, N. Kokuho, Y. Miura, H. Hayashi, T. Nei, K. Fujita, Y. Saito, A. Gemma, Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. *Respir Res* **15**, 16 (2014).
24. Y. Liu, S. P. Gunsten, D. H. Sultan, H. P. Luehmann, Y. Zhao, T. S. Blackwell, Z. Bollermann-Nowlis, J. H. Pan, D. E. Byers, J. J. Atkinson, D. Kreisel, M. J. Holtzman, R. J. Gropler, C. Combadiere, S. L. Brody, PET-based Imaging of Chemokine Receptor 2 in Experimental and Disease-related Lung Inflammation. *Radiology* **283**, 758-768 (2017).
25. Y. Liu, W. Li, H. P. Luehmann, Y. Zhao, L. Detering, D. H. Sultan, H. M. Hsiao, A. S. Krupnick, A. E. Gelman, C. Combadiere, R. J. Gropler, S. L. Brody, D. Kreisel, Noninvasive Imaging of CCR2(+) Cells in Ischemia-Reperfusion Injury After Lung Transplantation. *Am J Transplant* **16**, 3016-3023 (2016).
26. W. Li, H. P. Luehmann, H. M. Hsiao, S. Tanaka, R. Higashikubo, J. M. Gauthier, D. Sultan, K. J. Lavine, S. L. Brody, A. E. Gelman, R. J. Gropler, Y. Liu, D. Kreisel, Visualization of Monocytic Cells in Regressing Atherosclerotic Plaques by Intravital 2-Photon and Positron Emission Tomography-Based Imaging. *Arterioscler Thromb Vasc Biol*, (2018).
27. G. S. Heo, B. Kopecky, D. Sultan, M. Ou, G. Feng, G. Bajpai, X. Zhang, H. Luehmann, L. Detering, Y. Su, F. Leuschner, C. Combadiere, D. Kreisel, R. J. Gropler, S. L. Brody, Y. Liu, K. J. Lavine, Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart. *Circ Res* **124**, 881-890 (2019).
28. N. Limjunyawong, W. Mitzner, M. R. Horton, A mouse model of chronic idiopathic pulmonary fibrosis. *Physiol Rep* **2**, e00249 (2014).
29. T. Liu, F. G. De Los Santos, S. H. Phan, The Bleomycin Model of Pulmonary Fibrosis. *Methods Mol Biol* **1627**, 27-42 (2017).
30. B. B. Moore, C. M. Hogaboam, Murine models of pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* **294**, L152-160 (2008).
31. R. H. Hubner, W. Gitter, N. E. El Mokhtari, M. Mathiak, M. Both, H. Bolte, S. Freitag-Wolf, B. Bewig, Standardized quantification of pulmonary fibrosis in histological samples. *Biotechniques* **44**, 507-511, 514-507 (2008).
32. S. L. Gibbings, S. M. Thomas, S. M. Atif, A. L. McCubrey, A. N. Desch, T. Danhorn, S. M. Leach, D. L. Bratton, P. M. Henson, W. J. Janssen, C. V. Jakubzick, Three Unique

- Interstitial Macrophages in the Murine Lung at Steady State. *Am J Respir Cell Mol Biol* **57**, 66-76 (2017).
33. A. V. Misharin, L. Morales-Nebreda, G. M. Mutlu, G. R. Budinger, H. Perlman, Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. *Am J Respir Cell Mol Biol* **49**, 503-510 (2013).
34. B. Becher, A. Schlitzer, J. Chen, F. Mair, H. R. Sumatoh, K. W. Teng, D. Low, C. Ruedl, P. Riccardi-Castagnoli, M. Poidinger, M. Greter, F. Ginhoux, E. W. Newell, High-dimensional analysis of the murine myeloid cell system. *Nat Immunol* **15**, 1181-1189 (2014).
35. N. Joshi, A. V. Misharin, Single-nucleus isolation from frozen human lung tissue for single-nucleus RNA-seq. *Protocols.oi*, (2019).
36. C. J. Johnston, J. P. Williams, A. Elder, E. Hernady, J. N. Finkelstein, Inflammatory cell recruitment following thoracic irradiation. *Exp Lung Res* **30**, 369-382 (2004).
37. P. Gasse, N. Riteau, S. Charron, S. Girre, L. Fick, V. Petrilli, J. Tschopp, V. Lagente, V. F. Quesniaux, B. Ryffel, I. Couillin, Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. *Am J Respir Crit Care Med* **179**, 903-913 (2009).
38. P. Gasse, C. Mary, I. Guenon, N. Noulon, S. Charron, S. Schnyder-Candrian, B. Schnyder, S. Akira, V. F. Quesniaux, V. Lagente, B. Ryffel, I. Couillin, IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. *J Clin Invest* **117**, 3786-3799 (2007).
39. T. Hoshino, M. Okamoto, Y. Sakazaki, S. Kato, H. A. Young, H. Aizawa, Role of proinflammatory cytokines IL-18 and IL-1 β in bleomycin-induced lung injury in humans and mice. *Am J Respir Cell Mol Biol* **41**, 661-670 (2009).
40. R. G. Jenkins, B. B. Moore, R. C. Chambers, O. Eickelberg, M. Konigshoff, M. Kolb, G. J. Laurent, C. B. Nanthakumar, M. A. Oltman, A. Pardo, M. Selman, D. Sheppard, P. J. Sime, A. M. Tager, A. L. Tatler, V. J. Thannickal, E. S. White, A. T. S. A. o. R. Cell, B. Molecular, An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. *Am J Respir Cell Mol Biol* **56**, 667-679 (2017).
41. C. J. Schaefer, D. W. Ruhrmund, L. Pan, S. D. Seiwert, K. Kossen, Antifibrotic activities of pirfenidone in animal models. *Eur Respir Rev* **20**, 85-97 (2011).
42. W. Qin, B. Liu, M. Yi, L. Li, Y. Tang, B. Wu, X. Yuan, Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. *Radiat Res* **190**, 396-403 (2018).
43. L. Adamo, L. J. Staloch, C. Rocha-Resende, S. J. Matkovich, W. Jiang, G. Bajpai, C. J. Weinheimer, A. Kovacs, J. D. Schilling, P. M. Barger, D. Bhattacharya, D. L. Mann, Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. *JCI Insight* **3**, (2018).
44. P. F. Mercer, R. H. Johns, C. J. Scotton, M. A. Krupiczko, M. Konigshoff, D. C. Howell, R. J. McAnulty, A. Das, A. J. Thorley, T. D. Tetley, O. Eickelberg, R. C. Chambers, Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. *Am J Respir Crit Care Med* **179**, 414-425 (2009).
45. N. Joshi, S. Watanabe, R. Verma, R. P. Jablonski, C. I. Chen, P. Cheresch, N. S. Markov, P. A. Reyfman, A. C. McQuattie-Pimentel, L. Sichizya, Z. Lu, R. Piseaux-Aillon, D. Kirchenbuechler, A. S. Flozak, C. J. Gottardi, C. M. Cuda, H. Perlman, M. Jain, D. W.

- Kamp, G. R. S. Budinger, A. V. Misharin, A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages. *Eur Respir J* **55**, (2020).
46. K. Oda, H. Ishimoto, K. Yatera, K. Naito, T. Ogoshi, K. Yamasaki, T. Imanaga, T. Tsuda, H. Nakao, T. Kawanami, H. Mukae, High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. *Respir Res* **15**, 10 (2014).
47. J. Logan, J. S. Fowler, N. D. Volkow, G. J. Wang, Y. S. Ding, D. L. Alexoff, Distribution volume ratios without blood sampling from graphical analysis of PET data. *J Cereb Blood Flow Metab* **16**, 834-840 (1996).
48. M. A. Avila-Rodriguez, C. Rios, J. Carrasco-Hernandez, J. C. Manrique-Arias, R. Martinez-Hernandez, F. O. Garcia-Perez, A. R. Jalilian, E. Martinez-Rodriguez, M. E. Romero-Pina, A. Diaz-Ruiz, Biodistribution and radiation dosimetry of [(64)Cu]copper dichloride: first-in-human study in healthy volunteers. *EJNMMI Res* **7**, 98 (2017).
49. J. J. Osterholzer, M. A. Olszewski, B. J. Murdock, G. H. Chen, J. R. Erb-Downward, N. Subbotina, K. Browning, Y. Lin, R. E. Morey, J. K. Dayrit, J. C. Horowitz, R. H. Simon, T. H. Sisson, Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. *J Immunol* **190**, 3447-3457 (2013).
50. Y. Li, H. Li, S. Liu, P. Pan, X. Su, H. Tan, D. Wu, L. Zhang, C. Song, M. Dai, Q. Li, Z. Mao, Y. Long, Y. Hu, C. Hu, Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. *Mol Immunol* **99**, 134-144 (2018).
51. T. Win, N. J. Screaton, J. C. Porter, B. Ganeshan, T. M. Maher, F. Fraioli, R. Endozo, R. I. Shortman, L. Hurrell, B. F. Holman, K. Thielemans, A. Rashidnasab, B. F. Hutton, P. T. Lukey, A. Flynn, P. J. Ell, A. M. Groves, Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). *Eur J Nucl Med Mol Imaging* **45**, 806-815 (2018).
52. H. Liu, L. Gao, X. Yu, L. Zhong, J. Shi, B. Jia, N. Li, Z. Liu, F. Wang, Small-animal SPECT/CT imaging of cancer xenografts and pulmonary fibrosis using a (99m)Tc-labeled integrin alphavbeta6-targeting cyclic peptide with improved in vivo stability. *Biophys Rep* **4**, 254-264 (2018).
53. N. P. Withana, X. Ma, H. M. McGuire, M. Verdoes, W. A. van der Linden, L. O. Ofori, R. Zhang, H. Li, L. E. Sanman, K. Wei, S. Yao, P. Wu, F. Li, H. Huang, Z. Xu, P. J. Wolters, G. D. Rosen, H. R. Collard, Z. Zhu, Z. Cheng, M. Bogyo, Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes. *Sci Rep* **6**, 19755 (2016).
54. P. Desogere, L. F. Tapias, L. P. Hariri, N. J. Rotile, T. A. Rietz, C. K. Probst, F. Blasi, H. Day, M. Mino-Kenudson, P. Weinreb, S. M. Violette, B. C. Fuchs, A. M. Tager, M. Lanuti, P. Caravan, Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. *Sci Transl Med* **9**, (2017).
55. S. J. Gurczynski, M. C. Procaro, D. N. O'Dwyer, C. A. Wilke, B. B. Moore, Loss of CCR2 signaling alters leukocyte recruitment and exacerbates gamma-herpesvirus-induced pneumonitis and fibrosis following bone marrow transplantation. *Am J Physiol Lung Cell Mol Physiol* **311**, L611-627 (2016).
56. J. Kalliomaki, N. Attal, B. Jonzon, F. W. Bach, K. Huizar, S. Ratcliffe, B. Eriksson, M. Janecki, A. Danilov, D. Bouhassira, A. P. S. Group, A randomized, double-blind, placebo-

- controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. *Pain* **154**, 761-767 (2013).
57. S. G. Sayyed, M. Ryu, O. P. Kulkarni, H. Schmid, J. Lichtnekert, S. Gruner, L. Green, P. Mattei, G. Hartmann, H. J. Anders, An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. *Kidney Int* **80**, 68-78 (2011).
58. F. Tacke, Targeting hepatic macrophages to treat liver diseases. *J Hepatol* **66**, 1300-1312 (2017).
59. K. E. Lawlor, N. Khan, A. Mildenhall, M. Gerlic, B. A. Croker, A. A. D'Cruz, C. Hall, S. Kaur Spall, H. Anderton, S. L. Masters, M. Rashidi, I. P. Wicks, W. S. Alexander, Y. Mitsuuchi, C. A. Benetatos, S. M. Condon, W. W. Wong, J. Silke, D. L. Vaux, J. E. Vince, RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. *Nat Commun* **6**, 6282 (2015).
60. C. Plathow, M. Li, P. Gong, H. Zieher, F. Kiessling, P. Peschke, H. U. Kauczor, A. Abdollahi, P. E. Huber, Computed tomography monitoring of radiation-induced lung fibrosis in mice. *Invest Radiol* **39**, 600-609 (2004).
61. F. Dehdashti, R. Laforest, F. Gao, K. I. Shoghi, R. L. Aft, B. Nussenbaum, F. H. Kreisel, N. L. Bartlett, A. Cashen, N. Wagner-Johnston, R. H. Mach, Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. *J Nucl Med* **54**, 350-357 (2013).
62. M. G. Stabin, R. B. Sparks, E. Crowe, OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med* **46**, 1023-1027 (2005).
63. E. Z. Macosko, A. Basu, R. Satija, J. Nemesh, K. Shekhar, M. Goldman, I. Tirosh, A. R. Bialas, N. Kamitaki, E. M. Martersteck, J. J. Trombetta, D. A. Weitz, J. R. Sanes, A. K. Shalek, A. Regev, S. A. McCarroll, Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell* **161**, 1202-1214 (2015).
64. H. Wu, K. Uchimura, E. L. Donnelly, Y. Kirita, S. A. Morris, B. D. Humphreys, Comparative Analysis and Refinement of Human PSC-Derived Kidney Organoid Differentiation with Single-Cell Transcriptomics. *Cell Stem Cell* **23**, 869-881 e868 (2018).

Figure 1

Figure 1. CCR2⁺ cells localize to perifibrotic regions in bleomycin-induced lung fibrosis. C57BL/6 *Ccr2*^{gfp/+} mice were administered intranasal bleomycin and lungs assayed at the indicated day. **(A)** Representative images of CCR2-EGFP⁺ cells, identified using an anti-EGFP antibody (brown, top), with serial tissue sections stained using trichrome (bottom). **(B)** Quantitation of CCR2-EGFP⁺ cells in lung sections (0.14 mm² /field; approximately 250 fields/lung, n=3-5 mice/time point). **(C)** CCR2-EGFP⁺ cells in lung sections at each modified Ashcroft fibrosis score. Each cell count and fibrosis score are from the same field in serial sections. Significantly more CCR2-EGFP⁺ cells were in the regions with Ashcroft scores 5-7 than 0-4 at 14 and 28 days. **(D)** Representative pseudo-colored density plots from analysis of mass cytometry showing a shift in the percentage of CCR2-EGFP⁺ inflammatory monocytes (Ly6C^{high} monos) and interstitial macrophages (MΦ) in single cell preparations of whole mouse lungs, days 0 and 28 post-bleomycin. **(E)** Relative proportions of CCR2-EGFP⁺ myeloid cell populations at day 28 post-bleomycin identified by mass cytometry (n=5 mice/day). Cells in D and E were identified using the gating strategy in Supplementary Methods and Fig. S2. **(F)** Representative differences in transcription of myeloid single-cell populations isolated from lungs of wild-type mice (day 20). Single-cell RNA sequencing of cells was visualized using a uniform manifold approximation and

projection (UMAP) plot. Cell types clustered by identity. (G) Cells expressing *Ccr2* proinflammatory and profibrotic genes in interstitial macrophages post bleomycin. Significance in A and B was determined by Kruskal-Wallis with Dunn's Multiple Comparison test. In A, Bars=250 μ m.

Figure 2

Fig. 2. Detection of ^{64}Cu -DOTA-ECL1i uptake by PET/CT in bleomycin-induced lung fibrosis in mice. A-D. Mice given intranasal bleomycin were injected with ^{64}Cu -DOTA-ECL1i, prior to dynamic PET/CT imaging on the indicated day. Representative transverse images are shown of (A) Wild-type (WT), (B) *Ccr2* knockout (KO, $\text{CCR}^{\text{gfp/gfp}}$) at day 14, and (C) WT in competitive receptor studies (Blocking) at day 14. (D) Lung uptake from A-C. Shown are the medians of $n=6-10$ mice/day of mixed sexes compared to non-treated mice by Kruskal-Wallis with Dunn's Multiple Comparison test. Day 14 knockout (KO) mice uptake and blocking (BL) was

compared to day 14 control conditions using the Mann-Whitney U test. **(E)** Example of regional cellularity and fibrosis (red borders) in a trichrome-stained tissue section compared to CT and PET/CT-fused coronal sections at day 14 post bleomycin. In E, Bar=1000 μ m.

Figure 3

Fig. 3. Effect of IL-1 β blockade and pirfenidone treatment on ^{64}Cu -DOTA-ECL1i PET uptake in bleomycin-induced fibrosis. (A) Treatment scheme of wild-type mice administered intranasal bleomycin (i.n. BLM) treated with intraperitoneal (i.p.) IgG or anti-IL-1 β antibody three times weekly on days 10-28. (B) Representative trichrome-stained lung sections at day 28 (n=3 IgG, 7 IL-1 β mice/condition). (C) Ashcroft scores from lung sections (0.14 mm 2 /field; n=360-500 fields/mouse lung; (n=3/group IgG, n=4/group IL-1 β). (D) Representative images of serial lung tissue sections stained with trichrome (top) and *Ccr2* in situ hybridization (bottom) of

indicated condition at day 28. **(E)** Quantitation of *Ccr2* in situ hybridization at day 28 (1400-1900 fields/mouse lung; n=3-4 mice/condition). **(F)** Representative ^{64}Cu -DOTA-ECL1i PET/CT uptake in bleomycin-induced lung fibrosis in mice at day 28 treated as indicated. **(G)** PET uptake in lungs after indicated treatment (n=8-9 mice/condition). **(H)** Treatment scheme of mice administered bleomycin, treated with chow only (BLM) or chow containing pirfenidone (BLM+PFD) on days 10-28. **(I)** Representative trichrome-stained lung sections at day 28. **(J)** Ashcroft scores from lung sections (0.14 mm^2 /field; n=33-36 fields/lung; n=4 mice/condition). **(K)** Quantitation of *Ccr2* in situ hybridization at day 28 (1600-1900, 0.14 mm^2 fields/mouse lung; n=4 mice/condition). **(L)** Percent of lung interstitial macrophages ($\text{M}\Phi$, SiglecF $^+$ /CD64 $^+$) in single cell preparations of mouse lungs using mass cytometry (n=7-8 mice/condition). **(M)** Representative PET/CT images at day 28 treated as indicated. **(N)** PET uptake in lungs treated as indicated (n=8-9 mice/condition). Significance determined by Mann-Whitney U test for all data. Bars in B, I=1000 μm , D=100 μm .

Figure 4

Fig. 4. Detection of CCR2⁺ cells in lung tissue explanted from patients with pulmonary fibrosis. Explanted lungs from patients with end-stage pulmonary fibrosis (PF) or non-fibrotic lungs donated for research (Donor). (A) Pre-transplant chest CT from a patient with IPF showing the region of explanted lung sampled (*) for serial tissue sections stained by trichrome and CCR2 antibody (green). Arrows indicate pleural surface. Yellow lines demarcate regions of high CCR2⁺ cells. (B) Representative serial tissues of donor lung stained as in A. (C) Total CCR2⁺ cells in samples (n=4 donors, n=11 PF). (D) CCR2⁺ cells from donor and PF lungs. Box plots represent a sample from each subject. Brackets mark fields with CCR2⁺ cell density above the 95th percentile of fields of donors. (E) Percent of interstitial macrophages (MΦ) in lung tissues (median, n=6 donors, n=11 PF). (F) Representative comparison of trichrome, CCR2 staining, and ⁶⁴Cu-DOTA-ECL1i autoradiography in serial sections. Blocking studies confirm binding specificity (n=9). (G) Spearman correlation of CCR2 and corresponding ⁶⁴Cu-DOTA-ECL1i pixel intensity in fields of high and low CCR2 immunofluorescence (boxes) from F. In C and E, significance determined by

the Mann-Whitney U test. In A,B,E,F DAPI stained nuclei are blue. Bars in A,B=500 μ m; F=5 mm.

Figure 5

Fig. 5. Dosimetry testing of ^{64}Cu -DOTA-ECL1i PET/CT imaging in healthy volunteers. (A) Representative coronal images of CT, maximum intensity projection PET, and PET/CT from a healthy volunteer obtained at the indicated time following a single intravenous injection with ^{64}Cu -DOTA-ECL1i ($n=6$). PET images show uptake in liver, kidney, and bladder. Representative time-activity curves demonstrate **(B)** rapid blood clearance and **(C)** estimated renal clearance based on changes in bladder activity.

Figure 6

Fig. 6. ^{64}Cu -DOTA-ECL1i PET/CT imaging in patients with IPF. A healthy volunteer and subjects with IPF (n=4) were injected with ^{64}Cu -DOTA-ECL1i immediately prior to dynamic PET/CT imaging. (A) Representative sagittal plane CT, PET, and PET/CT-fused images showing subpleural uptake (arrows). Circled areas of non-fibrotic (yellow) and fibrotic (orange) lung were selected for Logan analysis. (B) Representative coronal plane images of lungs demonstrating subpleural uptake. (C) Logan plot demonstrates differing ^{64}Cu -DOTA-ECL1i binding in regions of non-fibrotic and fibrotic tissue identified on PET/CT images from IPF2. (D) Differences in distribution volume of ^{64}Cu -DOTA-ECL1i in non-fibrotic and fibrotic regions of IPF subjects (n=4). Significance determined by the Mann-Whitney U test. Images in (A) and (B) were arranged by increasing radiotracer uptake observed on PET.

Table 1. ⁶⁴Cu-DOTA-ECL1i PET uptake metrics of subjects with IPF

Subject	Age (years)	Sex	O ₂ use	FVC (%)	Fibrosis score*	ROI captured	Distribution volume	DV/ fibrosis ratio	SUV max	SUVmax fibrosis ratio
IPF1	70	M	No	102	108	Non-fibrotic	0.25	1.96	1.20	1.63
						Fibrosis	0.49		1.95	
IPF2	57	F	No	59	145	Non-fibrotic	0.22	2.63	0.75	2.64
						Fibrosis	0.58		1.98	
IPF3	75	M	No	92	131	Non-fibrotic	0.34	1.62	1.50	2.13
						Fibrosis	0.55		3.20	
IPF4	62	M	Yes	71	148	Non-fibrotic	0.33	2.18	2.70	2.20
						Fibrosis	0.72		5.93	

Abbreviations: FVC (%), Percent of predicted forced vital capacity; ROI, Region of interest; DV, Distribution volume; SUVmax, Maximum standard uptake value.

*Fibrosis score measured as described (46).